Literature DB >> 17072521

Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.

Rita Engenhart-Cabillic1, Ahmed Farhoud, Ulrich Sure, Stefan Heinze, Martin Henzel, Hans-Dieter Mennel, Helmut Bertalanffy.   

Abstract

BACKGROUND AND
PURPOSE: Although meningiomas are typically benign, they occasionally behave in an aggressive fashion and carry a less favorable prognosis. The aim of this study was to review the clinical, radiologic and histopathologic features of these aggressive variants as well as the outcome after multimodality therapy. PATIENTS AND METHODS: 16 patients with atypical meningiomas (n = 11) and anaplastic meningiomas (n = 5) were treated in the Departments of Neurosurgery and Radiation Oncology at the University Hospital of Philipps University Marburg, Germany, between 1997 and 2003. Tumor grading was based on new WHO criteria. There were eleven men and five women with a mean age of 54 years. The median follow-up period was 34 months.
RESULTS: A total of 24 surgical procedures were performed for these 16 patients. Only seven patients underwent postoperative fractionated stereotactic radiotherapy. Patients with atypical meningioma received radiotherapy only for the recurrent disease. Six patients (37.5%) experienced tumor recurrence after a mean period of 27.2 months in spite of gross total resection. Radiographic findings suggestive of aggressiveness were observed mostly with WHO grade III meningiomas. By comparing the proliferation rate in four cases with atypical meningioma operated twice, the recurrent tumor had a higher proliferation rate than the first tumor in three cases. A special proliferation pattern was noticed in MIB-1 with anaplastic meningiomas. The mean overall survival period was 66.5 months. There was no mortality among patients with atypical meningioma, while four out of five patients with anaplastic meningioma died during follow-up.
CONCLUSION: Considering the higher rate of recurrence in aggressive meningiomas even after radical surgical excision and the possibility that the recurrent tumor is more aggressive than the original one, surgery should be combined with postoperative fractionated radiotherapy to improve local tumor control. The peculiar focal expression patterns of anaplastic meningioma in MIB-1 might be a marker of such malignant development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17072521     DOI: 10.1007/s00066-006-1555-3

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  13 in total

1.  TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.

Authors:  Annamaria Biczok; Theo Kraus; Bogdana Suchorska; Nicole A Terpolilli; Jun Thorsteinsdottir; Armin Giese; Joerg C Tonn; Christian Schichor
Journal:  J Neurooncol       Date:  2018-05-28       Impact factor: 4.130

2.  Outcomes and complications of gamma knife radiosurgery for skull base meningiomas.

Authors:  Shyamal C Bir; Sudheer Ambekar; Tabitha Ward; Anil Nanda
Journal:  J Neurol Surg B Skull Base       Date:  2014-05-27

3.  Anatomic location is a risk factor for atypical and malignant meningiomas.

Authors:  Ari J Kane; Michael E Sughrue; Martin J Rutkowski; Gopal Shangari; Shanna Fang; Michael W McDermott; Mitchel S Berger; Andrew T Parsa
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

4.  Prospective, Randomized Study of Radiation Dose Escalation With Combined Proton-Photon Therapy for Benign Meningiomas.

Authors:  Nina N Sanford; Beow Y Yeap; Mykol Larvie; Juliane Daartz; John E Munzenrider; Norbert J Liebsch; Barbara Fullerton; Elizabeth Pan; Jay S Loeffler; Helen A Shih
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-07-12       Impact factor: 7.038

5.  Atypical and malignant meningioma: outcome and prognostic factors in 68 irradiated patients.

Authors:  Beatrice Detti; Silvia Scoccianti; Vanessa Di Cataldo; Eleonora Monteleone; Samantha Cipressi; Lorenzo Bordi; Gianni Pellicanò; Davide Gadda; Calogero Saieva; Daniela Greto; Guido Pecchioli; Annamaria Buccoliero; Marco Ceroti; Franco Ammannati; Giampaolo Biti
Journal:  J Neurooncol       Date:  2013-09-18       Impact factor: 4.130

6.  Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: the MARCIE trial.

Authors:  Stephanie E Combs; Lutz Edler; Iris Burkholder; Stefan Rieken; Daniel Habermehl; Oliver Jäkel; Thomas Haberer; Andreas Unterberg; Wolfgang Wick; Jürgen Debus; Renate Haselmann
Journal:  BMC Cancer       Date:  2010-11-09       Impact factor: 4.430

7.  Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma.

Authors:  Ayal A Aizer; Nils D Arvold; Paul Catalano; Elizabeth B Claus; Alexandra J Golby; Mark D Johnson; Ossama Al-Mefty; Patrick Y Wen; David A Reardon; Eudocia Q Lee; Lakshmi Nayak; Mikael L Rinne; Rameen Beroukhim; Stephanie E Weiss; Shakti H Ramkissoon; Malak Abedalthagafi; Sandro Santagata; Ian F Dunn; Brian M Alexander
Journal:  Neuro Oncol       Date:  2014-06-02       Impact factor: 12.300

8.  Rhabdoid meningioma: clinical features and MR imaging findings in 15 patients.

Authors:  E Y Kim; Y C Weon; S T Kim; H-J Kim; H S Byun; J-I Lee; J H Kim
Journal:  AJNR Am J Neuroradiol       Date:  2007-09       Impact factor: 3.825

Review 9.  State-of-the-art treatment alternatives for base of skull meningiomas: complementing and controversial indications for neurosurgery, stereotactic and robotic based radiosurgery or modern fractionated radiation techniques.

Authors:  Stephanie E Combs; Ute Ganswindt; Robert L Foote; Douglas Kondziolka; Jörg-Christian Tonn
Journal:  Radiat Oncol       Date:  2012-12-29       Impact factor: 3.481

10.  A retrospective analysis of survival and prognostic factors after stereotactic radiosurgery for aggressive meningiomas.

Authors:  Daniel J Ferraro; Ryan K Funk; John William Blackett; Michelle R Ju; Todd A DeWees; Michael R Chicoine; Joshua L Dowling; Keith M Rich; Robert E Drzymala; Imran Zoberi; Joseph R Simpson; Jerry J Jaboin
Journal:  Radiat Oncol       Date:  2014-01-27       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.